Breast Cancer Clinical Trial
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Summary
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
Adequate bone marrow, kidney and liver function.
Performance status of 0 or 1.
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion Criteria:
Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Los Angeles California, 90033, United States More Info
Contact
Newport Beach California, 92663, United States More Info
Contact
Washington District of Columbia, 20007, United States More Info
Contact
Sarasota Florida, 34232, United States More Info
Contact
Baltimore Maryland, 21201, United States More Info
Contact
Boston Massachusetts, 02215, United States More Info
Contact
Greenville South Carolina, 29605, United States More Info
Contact
Dallas Texas, 78701, United States More Info
Contact
How clear is this clinincal trial information?